Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Notice of Annual General Meeting of Shareholders Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. Pursuant to temporary emergency legislation regarding COVID-19 in The Netherlands, the AGM can only be accessed electronically. This means that it will not be possible to attend the AGM in person. Instead, the Company will provide instructions how t...
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 17 paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any so...
Delisting of Kiadis will be effective on 25 May 2021 This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch...
Sanofi completes Kiadis acquisition This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum dated 10 February 2021 (the “Offer Memorandum”), approved by the Dutch Authority for the Financial ...
Sanofi declares the Offer for Kiadis unconditional This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2 and Article 17 paragraph 1 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of an...
Kiadis employee options committed under the Sanofi Offer This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis launched on February 12, 2021 (the “Offer”). The Offer is made only by means of the offer memorandum approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) on February 10, 20...
Kiadis Pharma announces annual results for the year ended December 31, 2020 New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”, “Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces its audited 2020 annual results 1. Arthur Lahr, CEO of Kiadis, commented, “2020 can be described as...
Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi This is a press release by Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by Sanofi Foreign Participations B.V. (“the Offeror”), a wholly owned subsidiary of Sanofi (“Sanofi”), for all the issued and outstanding ordinary shares in the capital of Kiadis launched on February 12, 2021 (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the offer memorandum approved by t...
The independent financial analyst theScreener just awarded an improved star rating to KIADIS (NL), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 16, 2021, the closing...
Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis launched on 12 February 2020 (the “Offer”). The Offer is made only by means of the offer memorandum approved by the Dutch Authority for the Financial Mar...
AKKA: Update on restructuring costs in GE and FR Brunel International: Strong 4Q margin and cost efforts Crescent: FY20 will see Covid-19 delays and postponements Flow Traders: Blowout 4Q20 results Hal Trust: Soon to be listed cash? ING: FY20 beat. Quietly turning into a capital story Intertrust: Comforting 4Q20 results Inventiva: Cash at € 113m, ready for phase III launch in 1H21 IO&W: FY20: No surprises, still a great valuation play Kiadis: Launch of Sanofi tender offer X-FAB: Great set of res...
Sanofi launches recommended cash offer for all shares in Kiadis This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article 10 paragraph 1 and 3, and Article 18 paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the “Decree”) in connection with the intended public offer by the Offeror for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute...
Kiadis Shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the “Decree”) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the “Offer”). This announcement does not constitute an offer, or any solicitation of any offer, t...
Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that four abstracts related to its K-NK-cell therapy platform were accepted for presentation at the TCT Meeti...
Kiadis draws €20 million from bridge loan with Sanofi This is a press release by Kiadis Pharma N.V. pursuant to Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014) and in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis Pharma N.V. (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum approved by the Dutch Authority for the Financial Markets (Autorite...
Sanofi and Kiadis satisfy competition condition related to the tender offer This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) and Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014), in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the "Offer"). This announcement does not constitute an offer, or any solicitation of any...
Kiadis issues “holdback” shares to former Cytosen shareholders This is a press release by Kiadis Pharma N.V. (Kiadis), pursuant to the provisions of Sections 5 paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorand...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.